A Phase I Study of MK-4827 in Patients With Advanced Solid Tumors or Hematologic Malignancies.

Trial Profile

A Phase I Study of MK-4827 in Patients With Advanced Solid Tumors or Hematologic Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2013

At a glance

  • Drugs Niraparib (Primary)
  • Indications Advanced breast cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Solid tumours; T cell prolymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Jun 2013 Status changed from active, no longer recruiting to completed, according to results reported in Tesaro media release.
    • 04 Jun 2013 Results presented at ASCO 2013, according to Tesaro media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top